SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ma WW, Messersmith WA. Medical management of colorectal liver metastasis. In: GeschwindJFH, SoulenMC, eds. Interventional Oncology: Principles and Practice. New York, NY: Cambridge University Press; 2008: 222-242.
  • 2
    Vogl TJ, Zangos S, Eichler K, Yakoub D, Nabil M. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol. 2007; 17: 1025-1034.
  • 3
    Tellez C, Benson AB, Layster MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer. 1998; 82: 1250-1259.
  • 4
    Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355: 1041-1047.
  • 5
    de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18: 2938-2947.
  • 6
    Tournigand C, Andre T, Achille E, et al. FOLFIRI Followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22: 229-237.
  • 7
    Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343: 905-914.
  • 8
    Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003; 21: 60-65.
  • 9
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
  • 10
    Saltz LB, Clarke S, Dıaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26: 2013-2019.
  • 11
    Sanz-Altamira PS, Spence LD, Huberman MS, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma, a phase II trial. Dis Colon Rectum. 1997; 40: 770-775.
  • 12
    Bavisotto LM, Patel NH, Althaus SJ, et al. Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Pugent Sound Oncology Consortium. Clin Cancer Res. 1999; 5: 95-109.
  • 13
    Charnsangavej C. Chemoembolization of liver tumors. Semin Intervent Radiol. 1993; 10: 150-160.
  • 14
    Therase P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 15
    Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230: 309.
  • 16
    Jamison RL, Donohue JH, Nagorney DM, Rosen CB, Harmsen WS, Ilstrup DM. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997; 132: 505-510.
  • 17
    Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009; 27: 3677-3683.
  • 18
    Lang EK, Brown CL. Colorectal metastases to the liver: selective chemoembolization. Radiology. 1993; 189: 417-422.
  • 19
    Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Repeated Transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology. 2009; 250: 281-289.
  • 20
    Liapi E, Georiades CC, Hong K, Geschwind JH. Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol. 2007; 10: 2-11.
  • 21
    Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver: is there a survival difference? Meta-analysis of the published literature. Cancer. 1996; 78: 1639-1645.
  • 22
    Martinelli DJ, Wadler S, Bakal CW, et al. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer. 1994; 74: 1706-1712.
  • 23
    Britten CD, Finn RS, Gomes AS, et al. A pilot study of IV bevacizumab in hepatocellular cancer patients undergoing chemoembolization. J Clin Oncol. 2005; 23 (16 suppl): 413.
  • 24
    Britten C. A phase II study of rhuMAb VEGF (BEVACIZUMAB) in patients with hepatocellular carcinoma receiving chemoembolization. ClinicalTrials.gov Identifier: NCT00049322. Los Angeles, CA: Jonsson Comprehensive Cancer Center, National Cancer Institute; 2010.
  • 25
    Sato KT, Lewandowski RJ, Mulcahy MF, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres—safety, efficacy, and survival. Radiology. 2008; 247: 507-515.
  • 26
    Fiorentini G, Aliberti C, Turrisi G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo. 2007; 21: 1085-1091.
  • 27
    Martin RC, Joshi J, Robbins K, Tomalty D, O'Hara R, Tatum C. Transarterial Chemoembolization of Metastatic Colorectal Carcinoma with Drug-Eluting Beads, Irinotecan (DEBIRI): Multi-Institutional Registry. J Oncol. 2009; 2009: 539795.
  • 28
    Fiorentini G, Aliberti C, Benea G, et al. TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and postprocedure supportive therapy on the control of side effects. Hepatogastroenterology. 2008; 55: 2077-2082.
  • 29
    Soulen MC. Chemoembolization of hepatic malignancies. Oncology (Williston Park) 1994; 8: 77-84.